India’s bioeconomy is on the verge of reaching $200 billion, marking a significant milestone in its development. A recent report by Endiya Partners revealed that the country’s bioeconomy has surged from $10 billion in 2014 to over $195 billion in 2026, now contributing almost 5% to the GDP.
Known as the ‘Pharmacy of the World’ for its substantial supply of global generics and vaccines, India is shifting towards an innovation-driven biopharma ecosystem focusing on novel therapeutics and deep-tech platforms. The report emphasized that India is at a turning point, supported by favorable policies, regulatory reforms, and increasing global recognition of its clinical-stage assets.
Key government initiatives like the Biopharma Shakti scheme and the Research, Development, and Innovation Fund are set to boost the development of a robust innovation ecosystem. Regulatory reforms, such as streamlined approval processes and prior intimation pathways, are expected to cut administrative delays and shorten drug development timelines by up to four months.
Structural changes in the global biopharma sector, such as escalating R&D costs and an impending patent cliff worth $300 billion, are creating opportunities for efficient research hubs like India. Indian biotech startups benefit from faster patient recruitment, lower Phase II trial costs, and improved success rates in drug development compared to global counterparts.
Despite progress, challenges like infrastructure gaps, funding limitations, talent shortages, and research capacity gaps persist in India’s biopharma landscape. However, with over 2,500 startups, 100 incubators, and 600 research institutes, India’s biopharma ecosystem is poised for further growth, aiming to become a global center for cost-effective, high-quality biopharma innovation.
